RxDoctor Payments Data

Kimberly Ford, NP

Nurse Practitioner · Birmingham, ALNPI 1477160927

Payments from drug & device makers

$1,474in general payments, 2019–2025

Across 16 payments — averaging $92.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$366
  • AstraZeneca$187
  • HEMA Biologics, LLC$125
  • Gilead$124
  • Amgen$122
  • Otsuka America Pharmaceutical, Inc.$122
  • plus $429 from 7 others

What the payments were for

  • Food & beverage$1,474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$366
AstraZeneca2$187
HEMA Biologics, LLC1$125
Gilead1$124
Amgen1$122
Otsuka America Pharmaceutical, Inc.1$122
Johnson & Johnson1$117
Astellas Pharma US Inc1$115
Bayer1$115
Atland Pharmaceuticals, LLC1$38
Pfizer1$15
Exact Sciences1$15
Novo Nordisk1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,474 in reported general payments places this provider in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$210
Medicare patients
12
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$12,423
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,663
Albuterol Sulfate HfaAlbuterol Sulfate48$1,134
Potassium Chloride13$726
Atorvastatin Calcium64$488
Celecoxib11$413
Amlodipine Besylate58$329
Losartan Potassium32$324
Fluconazole19$320
Omeprazole19$283
Levothyroxine Sodium18$253
Duloxetine Hcl11$240
Quetiapine Fumarate15$211
Lisinopril25$197
Famotidine16$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$12,42311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →